Mounjaro is a GLP-1 receptor agonist intended for use when lifestyle measures such as diet and exercise alone do not adequately control blood glucose levels. The KwikPen device is a prefilled, multi-dose pen designed for ease of self-administration at home. Each pen contains four fixed doses of the specified strength: for example, a 2.5 mg pen holds a total of 10 mg of tirzepatide (4 doses × 2.5 mg), 0.6 ml each. Patients inject one dose per week, so each pen is designed to last for one month.

Many patients often ask how many doses are in Mounjaro 2.5 mg pen, and some also wonder whether it’s safe to take a different dose from a 2.5 mg Mounjaro pen. It’s important to follow the prescribed dosage exactly and not adjust doses manually, as the pen delivers fixed, pre-measured doses to ensure safe and effective blood-sugar control.

This GLP-1 medication is specifically indicated for type 2 diabetes and should not be used for type 1 diabetes or diabetic ketoacidosis. Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) must avoid this treatment. Always use Mounjaro under the supervision of a qualified healthcare provider.

Before starting this medicine, tell your doctor about all the medicines you are taking to avoid possible drug interactions. Check your blood sugar regularly and attend follow-up visits so your doctor can monitor your progress and adjust the dose if needed. Do not take this medicine on your own without medical advice. If you notice any unusual symptoms, contact your doctor immediately.

Mounjaro 2.5mg KwikPen is approved for:

• Improves blood sugar control in adults with type 2 diabetes mellitus through the action of a GLP-1 receptor agonist.

• Used in combination with diet and exercise for better glycaemic management.

• This GLP-1 medication may be used alone or together with other diabetes medicines, as prescribed by a healthcare provider.

Tirzepatide in this pen works as a GLP-1 receptor agonist, mimicking the action of two natural hormones in your body. These hormones help lower blood sugar in three key ways: by helping your body release insulin when needed, reducing how much sugar your liver produces, and slowing down how quickly food leaves your stomach. This GLP-1 mechanism helps you feel full for longer, reduces how much you eat, and keeps your blood sugar steady throughout the day.

Like most diabetes medications, this injection can interact with certain other drugs and affect how well it works or increase the risk of side effects. Inform your doctor about all the medicines you take, especially:

• Insulin or sulfonylureas: When taken together, the risk of low blood sugar increases. Dose adjustments may be needed.

• Oral contraceptives: Tirzepatide may reduce the effectiveness of birth control pills due to delayed gastric emptying. Alternative or additional contraceptive methods are advised.

• Warfarin: May affect INR levels. Close monitoring is essential if you are on blood thinners.

• Diuretics or antihypertensives: Sudden drops in blood pressure may occur, especially if dehydration happens due to nausea or vomiting.

• Thyroid medications: Use caution in patients with a history of thyroid issues, particularly medullary thyroid carcinoma.

Always carry a list of your medications to share with your doctor or pharmacist to prevent serious interactions.

• Store unused pens in the refrigerator between 2°C to 8°C.

• Do not freeze. Discard if frozen.

• Once in use, you can store the pen at room temperature (not above 30°C) for up to 21 days.

• Keep the pen capped and away from light and heat.

• Do not use the pen after the expiration date on the label.

Mounjaro 2.5mg KwikPen is a pre-filled pen designed for once-weekly subcutaneous injection. You can inject it into your abdomen, thigh, or upper arm. It can be taken with or without food, at any time of the day. Try to take it on the same day each week. Never share your pen, even if the needle is changed. Follow your doctor’s instructions for the correct dosing and handling.

Common Side Effects:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Decreased appetite

• Injection site reactions (redness, itching)

Serious Side Effects:

• Pancreatitis (severe abdominal pain)

• Gallbladder issues (pain in the upper right abdomen)

• Allergic reactions (rash, swelling, difficulty breathing)

• Kidney problems due to dehydration from vomiting or diarrhea

• Thyroid tumors (rare but serious; watch for neck swelling or hoarseness)

• Administer Mounjaro 2.5mg KwikPen on the same day each week to maintain consistent blood sugar control. Set a reminder to help you stay on track.

• To prevent skin irritation or lumps, administer the medication to different areas of the abdomen, thigh, or upper arm.

• Monitor blood sugar levels regularly to prevent hypoglycemia.

• Eat small, frequent, balanced meals, and avoid greasy, high-fat foods to reduce nausea.

• Drink plenty of water to help counteract potential dehydration caused by nausea, vomiting, or diarrhea.

• Be watchful for symptoms such as severe stomach pain, signs of pancreatitis (including severe upper abdominal pain that may radiate to the back, accompanied by nausea, vomiting, or fever), or allergic reactions. Consult a doctor immediately if these symptoms occur.

• Mounjaro 2.5mg KwikPen may reduce the effectiveness of oral hormonal contraceptives. Switch to a non-oral contraceptive method or use an additional barrier method (e.g., condoms) for 4 weeks after starting this medicine and for 4 weeks after each dose escalation.

• Let doctors know you're taking Mounjaro 2.5mg KwikPen before surgeries, as it may delay stomach emptying and increase aspiration risk.

• While Mounjaro 2.5mg KwikPen can aid in weight management, results take time, and maintaining a healthy lifestyle enhances its effectiveness.

1. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

2. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and

3. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses

4. https://pi.lilly.com/ca/mounjaro-ca-ifu-kp.pdf